Literature DB >> 21626153

Effects of artemether, artesunate and dihydroartemisinin administered orally at multiple doses or combination in treatment of mice infected with Schistosoma japonicum.

Hong-Jun Li1, Wei Wang, You-Zi Li, Guo-Li Qu, Yun-Tian Xing, Yong-Hui Tao, Jian-Ying Wei, Jian-Rong Dai, You-Sheng Liang.   

Abstract

Artemether and artesunate, derivatives of the antimalarial artemisinin, as well as their main metabolite, dihydroartemisinin, all exhibit antischistosomal activities. The purpose of the current study was to compare the effects of artemether, artesunate and dihydroartemisinin administered orally at multiple doses or combination in treatment of mice infected with Schistosoma japonicum. We carried out experiments with mice, infected with 40 cercariae of S. japonicum, and treated with artemether, artesunate and dihydroartemisinin (all at a single dose of 300 mg/kg, and the dose of the mixed three drugs is also 300 mg/kg) at multiple doses or combination therapy on days 6-8 or 34-36 post-infection. Administration with artemether, artesunate or dihydroartemisinin for 3 successive days reduced total worm burdens by 79.5-86% (30.86 ± 4.98 of mean total worm burden in control), female worm burdens by 79.4-86.7% (11.29 ± 2.63 of mean female worm burden in control) (all P values <0.01 vs. control), depending on different treatment protocols given on days 6-8 post-infection. However, no differences were seen between each treatment group (all P > 0.05). While the same treatment was given on days 34-36 post-infection, total worm burden reductions of 73.8-75.8% were achieved (29.44 ± 3.36 of mean total worm burden in control), which were significant when compared with the untreated control group (all P values <0.01). In all different treatment groups, female worm reductions (ranging from 88.7% to 93.1%, while the mean female worm burden in control is 10.33 ± 1.80) were consistently higher than the total worm reductions, resulting always in significantly lower female worm burdens when compared to the corresponding control (all P values < 0.01). However, there were no significant differences found between each treatment group (all P values >0.05). It is concluded that artemether, artesunate and dihydroartemisinin can be used to control schistosomiasis japonica, as a strategy to prevent S. japonicum infection. Administration with artemether, artesunate and dihydroartemisinin at multiple doses or in combined treatment damages both juvenile and adult S. japonicum, without statistically significant differences among the three drugs at the same dose.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21626153     DOI: 10.1007/s00436-011-2474-5

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  20 in total

Review 1.  Schistosomiasis--a century searching for chemotherapeutic drugs.

Authors:  Gabriela Ribeiro-dos-Santos; Sergio Verjovski-Almeida; Luciana C C Leite
Journal:  Parasitol Res       Date:  2006-04-25       Impact factor: 2.289

Review 2.  Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins.

Authors:  Shu-Hua Xiao
Journal:  Acta Trop       Date:  2005-08-19       Impact factor: 3.112

3.  Will new antischistosomal drugs finally emerge?

Authors:  Donato Cioli; Cristiana Valle; Francesco Angelucci; Adriana E Miele
Journal:  Trends Parasitol       Date:  2008-07-31

Review 4.  Research and development of antischistosomal drugs in the People's Republic of China a 60-year review.

Authors:  Shu-Hua Xiao; Jennifer Keiser; Ming-Gang Chen; Marcel Tanner; Jürg Utzinger
Journal:  Adv Parasitol       Date:  2010       Impact factor: 3.870

5.  The sensitivity of artesunate against Schistosoma japonicum decreased after 10 years of use in China.

Authors:  Hai-Yong Hua; You-Sheng Liang; Yan Zhang; Ji-Fu Wei; Hong-Xiong Guo
Journal:  Parasitol Res       Date:  2010-06-15       Impact factor: 2.289

6.  Artemether shows promising female schistosomicidal and ovicidal effects on the Egyptian strain of Schistosoma mansoni after maturity of infection.

Authors:  Rashad Abdul-Ghani; Naguiba Loutfy; Manal Sheta; Azza Hassan
Journal:  Parasitol Res       Date:  2010-11-25       Impact factor: 2.289

7.  Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice.

Authors:  Jürg Utzinger; Jacques Chollet; Zuwu Tu; Shuhua Xiao; Marcel Tanner
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 May-Jun       Impact factor: 2.184

8.  In vitro schistosomicidal activity of curcumin against Schistosoma mansoni adult worms.

Authors:  Lizandra G Magalhães; Carla Botelho Machado; Enyara Rezende Morais; Erika Bueno de Carvalho Moreira; Cláudia Sossai Soares; Sérgio Henrique da Silva; Ademar A Da Silva Filho; Vanderlei Rodrigues
Journal:  Parasitol Res       Date:  2008-12-19       Impact factor: 2.289

9.  The in vitro effect of mefloquine and praziquantel against juvenile and adult Schistosoma japonicum.

Authors:  Shu-Hua Xiao; Jing-Yan Mei; Pei-Ying Jiao
Journal:  Parasitol Res       Date:  2009-10-23       Impact factor: 2.289

Review 10.  Praziquantel.

Authors:  Donato Cioli; Livia Pica-Mattoccia
Journal:  Parasitol Res       Date:  2002-11-22       Impact factor: 2.289

View more
  11 in total

1.  Effect of the in vivo activity of dihydroartemisinin against Schistosoma mansoni infection in mice.

Authors:  Hong-jun Li; Wei Wang; Guo-li Qu; You-zi Li; Yong-hui Tao; Yun-tian Xing; Xiao-ting Wang; Yang Dai; Jian-ying Wei; Jian-rong Dai; Gerald C Coles; You-sheng Liang
Journal:  Parasitol Res       Date:  2011-10-18       Impact factor: 2.289

Review 2.  A review of dihydroartemisinin as another gift from traditional Chinese medicine not only for malaria control but also for schistosomiasis control.

Authors:  Xu-Guang Zhang; Gui-Xin Li; Shu-Shun Zhao; Fu-Liang Xu; Yun-Hai Wang; Wei Wang
Journal:  Parasitol Res       Date:  2014-03-08       Impact factor: 2.289

3.  Artemisinin: the gifts from traditional Chinese medicine not only for malaria control but also for schistosomiasis control.

Authors:  Rong Liu; Hui-Fen Dong; Ming-Sen Jiang
Journal:  Parasitol Res       Date:  2011-10-27       Impact factor: 2.289

4.  In vitro and in vivo activity of 3-alkoxy-1,2-dioxolanes against Schistosoma mansoni.

Authors:  Katrin Ingram; Charles E Schiaffo; Wantanee Sittiwong; Evan Benner; Patrick H Dussault; Jennifer Keiser
Journal:  J Antimicrob Chemother       Date:  2012-05-02       Impact factor: 5.790

5.  Artemether Exhibits Amoebicidal Activity against Acanthamoeba castellanii through Inhibition of the Serine Biosynthesis Pathway.

Authors:  Yihong Deng; Wei Ran; Suqin Man; Xueping Li; Hongjian Gao; Wei Tang; Hiroshi Tachibana; Xunjia Cheng
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

Review 6.  Present-day anthelmintics and perspectives on future new targets.

Authors:  Amira Taman; Manar Azab
Journal:  Parasitol Res       Date:  2014-06-04       Impact factor: 2.289

7.  Is there a reduced sensitivity of dihydroartemisinin against praziquantel-resistant Schistosoma japonicum?

Authors:  Wei Wang; Hong-Jun Li; Guo-Li Qu; Yun-Tian Xing; Zhen-Kun Yang; Jian-Rong Dai; You-Sheng Liang
Journal:  Parasitol Res       Date:  2013-10-22       Impact factor: 2.289

8.  Dihydroartemisinin: a new story of an old drug against Schistosoma mansoni infection.

Authors:  Hong-Jun Li; Fu-Liang Xu; Yun-Hai Wang; Zheng-Jun Yi; Wei Wang
Journal:  Parasitol Res       Date:  2013-10-22       Impact factor: 2.289

9.  LC-UV/MS quality analytics of paediatric artemether formulations.

Authors:  Kirsten Vandercruyssen; Matthias D'Hondt; Valentijn Vergote; Herwig Jansen; Christian Burvenich; Bart De Spiegeleer
Journal:  J Pharm Anal       Date:  2013-04-25

Review 10.  New uses for old drugs: the tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China.

Authors:  Yi-Xin Liu; Wei Wu; Yue-Jin Liang; Zu-Liang Jie; Hui Wang; Wei Wang; Yi-Xin Huang
Journal:  Molecules       Date:  2014-09-19       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.